BTI Stock Analysis: British American Tobacco | NYSE
Tobacco | NYSE, USA | Market Cap: 135.548m USD | 12M Return: 35.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 271M
EPS Trend: -26.3%
Qual. Beats: 0
Rev. Trend: 97.1%
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
British American Tobacco p.l.c. (BTI) is a UK-headquartered, multinational tobacco and nicotine company founded in 1902 and listed on the NYSE. It operates across the Americas, Europe, Asia-Pacific, the Middle East, Africa, and other regions, distributing its products through retail outlets.
BATs portfolio spans multiple product categories, including vapour products (Vuse), heated tobacco (glo), modern oral nicotine pouches (Velo), traditional oral products such as snus and moist snuff, combustibles (cigarettes), and fine cut/roll-your-own tobacco. The company markets a wide roster of brands, including Newport, Camel, Natural American Spirit, Lucky Strike, Pall Mall, Dunhill, Kent, and Rothmans, alongside Grizzly, Kodiak, and Vogue.
As a large-cap Consumer Staples constituent in the Tobacco sub-industry, BAT is pursuing a multi-category strategy that extends well beyond traditional cigarettes, reflecting the broader tobacco sectors transition toward reduced-risk and next-generation nicotine products as combustible volumes face structural pressure.
- US combustible volume decline offset by premium pricing power
- FDA regulation threatens menthol and flavored product sales
- Vuse and Velo next-generation products drive margin expansion
| Net Income: 7.76b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.71 > 1.0 |
| NWC/Revenue: -7.18% < 20% (prev -17.20%; Δ 10.01% < -1%) |
| CFO/TA 0.05 > 3% & CFO 5.73b > Net Income 7.76b |
| Net Debt (31.8b) to EBITDA (12.6b): 2.52 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (2.20b) vs prev -1.17% < -2% |
| Gross Margin: 83.50% > 18% (prev 82.85%; Δ 0.65% > 0.5%) |
| Asset Turnover: 22.45% > 50% (prev 21.76%; Δ 0.69% > 0%) |
| Interest Coverage Ratio: 6.60 > 6 (EBIT TTM 10.5b / Interest Expense TTM 1.59b) |
| A: -0.02 (Total Current Assets 12.7b - Total Current Liabilities 14.5b) / Total Assets 109b |
| B: 0.21 (Retained Earnings 22.9b / Total Assets 109b) |
| C: 0.09 (EBIT TTM 10.5b / Avg Total Assets 114b) |
| D: 0.78 (Book Value of Equity 47.9b / Total Liabilities 61.1b) |
| Altman-Z'' = 2.02 = BBB |
| DSRI: 1.35 (Receivables 3.80b/2.85b, Revenue 25.6b/25.9b) |
| GMI: 0.99 (GM 82.85% / 83.50%) |
| AQI: 1.00 (AQ_t 0.84 / AQ_t-1 0.84) |
| SGI: 0.99 (Revenue 25.6b / 25.9b) |
| TATA: 0.02 (NI 7.76b - CFO 5.73b) / TA 109b) |
| Beneish M = -2.75 (Cap -4..+1) = A |
As of July 02, 2026, the stock is trading at USD 60.56 with a total of 4,718,628 shares traded. Over the past week, the price has changed by -1.35%, over one month by -0.72%, over three months by +4.61% and over the past year by +35.28%.
Current recommended Stop Loss: 57.20 (which is 5.5% or 2.6 ATR below the current price).
British American Tobacco has received a consensus analysts rating of 3.40. Therefore, it is recommended to hold BTI.
- StrongBuy: 1
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 68.4 | 13% |
Market Cap GBP = 102b (136b USD * 0.7547 USD.GBP)
P/E Trailing = 13.6732
P/E Forward = 13.0548
P/S = 5.2928
P/B = 2.1485
P/EG = 1.6453
Revenue TTM = 25.6b GBP
EBIT TTM = 10.5b GBP
EBITDA TTM = 12.6b GBP
Long Term Debt = 31.3b GBP (from longTermDebt, last quarter)
Short Term Debt = 3.36b GBP (from shortTermDebt, last quarter)
Debt = 35.6b GBP (from shortLongTermDebtTotal, last quarter) + Leases 529.0m
Net Debt = 31.8b GBP (calculated: Debt 35.6b - CCE 3.84b)
Enterprise Value = 134b GBP (102b + Debt 35.6b - CCE 3.84b)
Interest Coverage Ratio = 6.60 (Ebit TTM 10.5b / Interest Expense TTM 1.59b)
EV/FCF = 23.15x (Enterprise Value 134b / FCF TTM 5.79b)
FCF Yield = 4.32% (FCF TTM 5.79b / Enterprise Value 134b)
FCF Margin = 22.61% (FCF TTM 5.79b / Revenue TTM 25.6b)
Net Margin = 30.32% (Net Income TTM 7.76b / Revenue TTM 25.6b)
Gross Margin = 83.50% ((Revenue TTM 25.6b - Cost of Revenue TTM 4.23b) / Revenue TTM)
Gross Margin QoQ = 83.42% (prev 83.59%)
Tobins Q-Ratio = 1.23 (Enterprise Value 134b / Total Assets 109b)
Interest Expense / Debt = 4.48% (Interest Expense 1.59b / Debt 35.6b)
Taxrate = 21.24% (2.09b / 9.86b)
NOPAT = 8.29b (EBIT 10.5b * (1 - 21.24%))
Current Ratio = 0.87 (Total Current Assets 12.7b / Total Current Liabilities 14.5b)
Debt / Equity = 0.74 (Debt 35.6b / totalStockholderEquity, last quarter 47.9b)
Debt / EBITDA = 2.52 (Net Debt 31.8b / EBITDA 12.6b)
Debt / FCF = 5.48 (Net Debt 31.8b / FCF TTM 5.79b)
Total Stockholder Equity = 49.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.80% (Net Income 7.76b / Total Assets 109b)
RoE = 15.64% (Net Income TTM 7.76b / Total Stockholder Equity 49.6b)
RoCE = 12.99% (EBIT 10.5b / Capital Employed (Equity 49.6b + L.T.Debt 31.3b))
RoIC = 8.56% (NOPAT 8.29b / Invested Capital 96.8b)
WACC = 4.85% (E(102b)/V(138b) * Re(5.31%) + D(35.6b)/V(138b) * Rd(4.48%) * (1-Tc(0.21)))
Discount Rate = 5.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -79.57 | Cagr: -1.35%
[DCF] Terminal Value 73.10% ; FCFF base≈7.28b ; Y1≈6.39b ; Y5≈5.16b
[DCF] Fair Price = 23.64 (EV 82.8b - Net Debt 31.8b = Equity 51.1b / Shares 2.16b; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -26.32 | EPS CAGR: -54.01% | SUE: 0.0 | # QB: 0
Revenue Correlation: 97.05 | Revenue CAGR: 34.37% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=4.84 | Chg30d=-1.16% | Revisions=+20% | GrowthEPS=+0.8% | GrowthRev=+2.3%
EPS next Year (2027-12-31): EPS=5.25 | Chg30d=-1.24% | Revisions=+20% | GrowthEPS=+8.5% | GrowthRev=+3.5%
[Analyst] Revisions Ratio: +20%